Neuraxis
NRXS • AMEX
Neuraxis is a biotechnology company in the healthcare sector trading on AMEX, led by CEO Brian Carrico, with a market cap of $77.2M.
CEOBrian Carrico
Next Earnings
Upcoming earnings announcement for Neuraxis
Date
Monday, May 11, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.20
Revenue Estimate
$1.4M
Earnings History
Past 11 earnings reports for Neuraxis
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 19, 2026 | Q4 2025 | -$0.17Est: -$0.21 | +19.0% | $968.1KEst: $850.0K | +13.9% |  10-K |
| Nov 10, 2025 | Q3 2025 | -$0.24Est: -$0.20 | -20.0% | $811.4KEst: $1.0M | -18.9% | 10-Q |
| Aug 12, 2025 | Q2 2025 | -$0.22Est: -$0.19 | -15.8% | $894.1KEst: $983.6K | -9.1% | 10-Q |
| May 12, 2025 | Q1 2025 | -$0.33 | — | $895.7K | — | 10-Q |
| Mar 20, 2025 | Q4 2024 | -$0.23 | — | $761.2K | — | 10-K |
| Nov 12, 2024 | Q3 2024 | -$0.25 | — | $666.6K | — | 10-Q |
| Aug 9, 2024 | Q2 2024 | -$0.42 | — | $611.5K | — | 10-Q |
| May 22, 2024 | Q1 2024 | -$0.32 | — | $646.6K | — | 10-Q |
| Apr 16, 2024 | Q4 2023 | -$0.85 | — | $531.5KEst: $1.6M | -67.0% | 10-K |
| Nov 20, 2023 | Q3 2023 | -$1.35Est: -$0.17 | -694.1% | $477.5KEst: $1.4M | -66.1% | — |
| Sep 21, 2023 | Q2 2023 | -$1.21 | — | $646.0K | — | 10-Q |